Economic burden of hepatitis C‐associated diseases in the United States

  title={Economic burden of hepatitis C‐associated diseases in the United States},
  author={Antoine C. El Khoury and William K. Klimack and Carolyn Wallace and Homie Razavi},
  journal={Journal of Viral Hepatitis},
Summary.  There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data sources for hepatitis C in the United States. A systematic literature search was conducted to identify studies reporting the costs of hepatitis C sequelae in the… 

Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas

Knowing the burden of hepatitis C sequelae is useful for policy decisions as well as serving as a basis for determining the value of HCV screening and treatment.

The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia.

Findings from this review identified early detection as the first line of a preventive strategy to help reduce the evolving epidemic and that oral medications could reduce the risk of liver cancer and death.

Economic Burden of Hepatitis C Infection.

Economic burden of chronic viral hepatitis C

The analysis showed that interest in assessing the global burden of CVHC began to appear in recent years, when expensive directacting antivirals for the treatment appeared, and the results may be useful in conducting such studies, including the determining of their design and the use of modern mathematical modeling tools.

Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy

The clinical and economic burden of EHMs is substantial and can be reduced through viral eradication, especially if treatment is initiated early and not delayed until fibrosis advances, as well as within 3 to 6 years by savings in all‐cause medical costs.

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States

This analysis demonstrates that US HCV prevalence is in decline due to a lower incidence of infections, however, the prevalence of advanced liver disease will continue to increase as well as the corresponding healthcare costs.

Health Affairs Capacity Is A Concern Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains , But Dieterich and

Treating patients at all disease stages could generate $610–$1,221 billion in additional qualityadjusted life-years, plus an additional $139 billion in saved medical expenditures over fifty years, and minimize the disease burden, but upfront treatment costs would exceed $150 billion.

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals

Without large screening programs, elimination of HCV cannot be achieved and the HCV elimination strategy is feasible and cost-saving despite the uncertainty of the future cost of DAAs in Greece.

Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.

Treating patients at all disease stages could generate $610-$1,221 billion in additional quality-adjusted life-years, plus an additional $139 billion in saved medical expenditures over fifty years, and minimize the disease burden, but up-front treatment costs would exceed $150 billion.

Non-healthcare costs of hepatitis C: a systematic review

There is an increasing interest in the indirect (or non- healthcare) costs of hepatitis C virus (HCV) and there is a need for studies addressing non-healthcare costs of HCV in settings where new treatments with DAAs have been implemented, as they are probably changing the current and future burden of the disease.



Estimating future hepatitis C morbidity, mortality, and costs in the United States.

The results confirm prior Centers for Disease Control and Prevention projections and suggest that HCV may lead to a substantial health and economic burden over the next 10 to 20 years.

Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C

A decision analytic model was developed to project the immediate responses to treatment and predict the long-term outcomes on the basis of current natural history data to determine whether treatment of histologically mild chronic hepatitis C with a single 6-month course of interferon-2b would affect life expectancy and lifelong costs.

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.

Routine liver biopsy before treatment with interferon increases the cost of managing patients with CHC without improving health outcomes, and quantitative HCV RNA testing to guide therapy misses some potential sustained responders.

The burden of hepatitis C in the United States

Future projections predict a 4‐fold increase between 1990 and 2015 in persons at risk of chronic liver disease (i.e., those with infection for 20 years or longer), suggesting a continued rise in the burden of HCV in the United States in the foreseeable future.

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions.

Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population

Estimating all-cause and disease-related resource utilization and costs among managed care enrollees with chronic hepatitis C virus (HCV) found chronic HCV is a costly disease to managed care organizations and increased efforts in HCV screening and early treatment may lead to long-term cost savings.

Hepatitis C and injecting drug use: impact, costs and policy options.

Analysis of the impact and costs of hepatitis C among injecting drug users are presented, as a basis for sound policy-making, and issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy.

Economic burden of hepatitis C in Canada and the potential impact of prevention

This Canadian hepatitis C model estimates economic burden of disease using Markov modeling to predict progression over 11 health states annually from 2001 to 2040 to demonstrate the capability to determine cost- effectiveness of programs to prevent different proportions of incident cases.

Costs of hepatitis C.

This estimate of the direct and indirect costs of the hepatitis C virus (HCV) in the United States in 1997 is nearly 10 times the original estimate, and is on a par with the cost of asthma.